John Ripple – CEO
Prior to joining Ensemble in 2013, John served as CEO at Virdante Pharmaceuticals (acquired by Momenta Pharmaceuticals in 2011), and CEO of Syntonix Pharmaceuticals (acquired by Biogen Idec in 2006). Concurrent with his role as CEO of Ensemble, John continues in his role as CEO of Permeon Biologics in Cambridge, a company that, like Ensemble, is included in the portfolio of Flagship Ventures and ARCH Ventures and is also based on technology from the laboratory of Harvard University’s Prof. David Liu. Mr. Ripple has held positions in business development at Syntonix, Wyeth Pharmaceuticals, and Genetics Institute. His other business experiences include medical device marketing and management consulting. John started his career as an aerospace engineer at NASA. Mr. Ripple also serves on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA). He is an advisor to the MIT Deshpande Center for Technological Innovation and the MIT Venture Mentoring Service. He received a B.S. in Mechanical Engineering from Bucknell University and an M.B.A. from Harvard Business School.
Nick K. Terrett, Ph.D. - Chief Scientific Officer
Nick joined Ensemble Therapeutics as the Chief Scientific Officer in May
of 2006. In his role as CSO, Nick heads up our drug discovery program
investigating the rapid synthesis of macrocycles using DNA-Programmed
Chemistry, as drug candidates for disease relevant protein-protein
and protease targets.
After working as a medicinal chemist for Glaxo, Nick joined Pfizer in
Sandwich, England in 1984. He worked initially in cardiovascular disease,
and is an inventor on patents for the neutral endopeptidase inhibitor
candoxatrilat. Later he led the chemistry team on cGMP PDE inhibitors
for angina and erectile dysfunction, and is an inventor on patents for
Viagra®. Subsequently, Nick established Pfizer’s combinatorial
chemistry group and authored several related papers and a textbook. He
also managed the high throughput screening group and materials management,
and played a key role in the global integration of the Pfizer, Warner-Lambert
and Pharmacia compound collections. In 2003 Nick moved to the Pfizer
Research Technology Center in Cambridge, Massachusetts, to lead the Chemical
Sciences group investigating new targets for drug discovery and new chemistry
Nick has a B.A. and Ph.D. in
Natural Sciences from Cambridge University.
Ted Hibben - Senior Vice President, Corporate Development
Ted joined Ensemble Therapeutics in September 2010 as Senior Vice President, Corporate Development. He brings to Ensemble nearly 20 years of biotech experience in business and corporate development and strategy, venture fundraising, M&A and on leadership teams associated with a variety of early-to-mid development stage therapeutic technology platforms addressing inflammation, cancer, autoimmune and infectious diseases. Ted came to Ensemble from Cequent Pharmaceuticals, a company developing therapeutics based on RNAi, where he was Chief Business Officer and played a key role in effecting Cequent’s $46 million merger with MDRNA, Inc. (now Marina Biotech). Prior to Cequent, he was Vice President, Business Development and Alliance Management at Coley Pharmaceutical Group where he sourced and/or managed nine development collaborations and led the process to sell Coley to Pfizer for $233 million in 2008. Earlier, Ted was integral to advancing Centagenetix’s merger with Elixir, Ontogeny’s merger with Creative BioMolecules to form Curis, and Marathon Biopharmaceutical’s acquisition by Ligand.
Ted earned his M.B.A. from Harvard University and his A.B. from Dartmouth College.
Stephen P. Hale, Ph.D. - Senior Vice President, Biological Sciences
Stephen joined Ensemble Therapeutics in 2006 as Senior Director, Biology. Prior to Ensemble, Dr. Hale was at Praecis Pharmaceuticals for four years as Senior Director of Lead Discovery responsible for all biological aspects of the preclinical drug discovery program. He was a key inventor, leader in the implementation, and involved in business development of the Direct Select drug discovery platform. The value of the platform subsequently led to the acquisition of Praecis by GlaxoSmithKline plc. In his prior experience, he was a founding scientist at Phylos Inc. and held positions of increasing responsibility in both the microarray and therapeutic areas over his 5 year tenure. At Phylos Inc., Dr. Hale was a leader in the development of diagnostic protein arrays and the concurrent development of a preclinical pipeline of protein therapeutics, namely antibodies and antibody-mimic molecules. He led the team at Phylos Inc. responsible for the identification of a human fibronectin-based VEGF/KDR antagonist that was acquired by Adnexus Therapeutics Inc. and is currently in clinical trials. Dr. Hale was also a consultant to Cubist Pharmaceuticals and involved in early work at Genex Inc. on the design and engineering of single-chain antibodies as commercial alternatives to full-length antibodies.
He received his Ph.D in biochemistry from the University of Maryland, College Park, and was a National Institutes of Health post-doctoral fellow at the Massachusetts Institute of Technology under the direction of Professor Paul Schimmel.
Andrea Szekely-Hill, CPA - Senior Director, Finance & Administration
Andrea joined Ensemble Therapeutics as Controller and has served in roles of increasing financial and operational responsibility since that time. Prior to joining Ensemble, she served as an Audit Senior Manager in the Technology, Media, and Telecommunications group at Deloitte where she worked with early stage clients in the Life Sciences and Technology industries. Prior to Deloitte, she was an Assistant Vice President at State Street Research & Management responsible for budgeting and financial reporting.
Andrea received her B.S. in Accounting from Villanova University and is a member of the American Institute of Certified Public Accountants.